CeBIL - Center for Advanced Studies in Bioscience Innovation Law

Collaboration

CeBIL is international and interdisciplinary. Anchored at the Faculty of Law, the Centre is led by founding director Professor Timo Minssen. CeBIL collaborates with key national and international experts from academia, public bodies, patient organizations and industry. Some of the most renowned international academic capacities in biomedical innovation law are involved in the CeBIL-program as either Core Partners or Collaborators. The Core Partners of the CeBIL-program are listed below.

CORE PARTNERS
	Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) at the Faculty of Law Principal Investigator Professor Timo Minssen and his CeBIL team contribute with legal expertise in Intellectual Property Law, Competition Law, Data Protection and Regulatory Law in the Health and Life Sciences. Department of Food and Resource Economics (IFRO), UCPH Associate Professor Marcel Bogers and Assistant Professor Karin Beukel from the Unit for Innovation, Entrepreneurship and Management at IFRO contributes with expertise in the economics and management of innovation with a specific focus on analysis and methodology and special skills in IP management, business models and open innovation.
	Centre for Law, Medicine and Life Sciences, University of Cambridge Director, Dr. Kathleen Liddell contributes with expertise on intellectual property rights, patents and translational medicine. In addition, Professor Lionel Bentley (IP, trademarks, patents), Dr. Jeffrey Skopek (ethics, big data, personalised medicine), Dr. Stuart Hogarth (empirical studies, biomedical innovation, regulatory governance) and Dr. Mateo Aboy (biomedical engineering, patents, IP landscaping big data) participates and contributes to CeBIL.
	Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics, Harvard Law School Faculty Director, Professor I.G. Cohen. Cohen contributes with expertise on the intersection of bioethics/medical ethics and the law with a specific focus on big data, policy and translational medicine.
	PORTAL - Program on Regulation, Therapeutics and Law, Harvard Medical School and Brigham & Women’s Hospital Head of PORTAL, Professor Aaron Kesselheim, along with his team, Dr. Michael Sinha and Dr. Jonathan Darrow, contributes with both medical and legal expertise in relation to a.o. antibiotics, pharmaceutical development, and patents.
	University of Michigan Law School Dr. Nicholson Price contributes with special expertise in drug manufacturing, patent law, regulatory governance, health law, personalized medicine, big data.